FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma

Table 1 Clinical characteristics and genomic profiling of PC GC and non-PC GC patients (N = 556)

	No. of patients	PC n = 64 (%)	Non-PC n = 492 (%)	P^b
Age (years)	556			0.004
< 60	270	42 (65.6%)	228 (46.3%)
≥ 60	286	22 (34.4%)	264 (53.7%)
Gender	556			0.208
Male	369	38 (59.4%)	331 (67.3%)
Female	187	26 (40.6%)	161 (32.7%)
MSI status	545			0.085
MSS	516	64 (100%)	452 (91.8%)
MSI-H	29	0 (0%)	29 (5.9%)
TMB^a	556			0.001
TMB-L	411	58 (90.6%)	353 (71.7%)
TMB-H	145	6 (9.4%)	139 (28.3%)
Gene SNVs and INDELs
TP53	349	30 (46.9%)	319 (64.8%)	0.005
CDH1	80	18 (28.1%)	62 (12.6%)	0.001
ARID1A	98	9 (14%)	89 (18.1%)	0.426
ERBB2	29	6 (9.4%)	23 (4.7%)	0.196
CDKN2A	17	4 (6.3%)	13 (2.6%)	0.234
RHOA	32	4 (6.3%)	28 (5.7%)	1.000
SMAD4	33	2 (3.1%)	31 (6.3%)	0.465
Gene CNVs
FGFR2	33	8 (12.5%)	25 (5.1%)	0.037
CCNE1	63	2 (3.1%)	61 (12.4%)	0.028
ERBB2	42	1 (1.6%)	41 (8.3%)	0.094
VEGFA	28	1 (1.6%)	27 (5.5%)	0.295
Gene rearrangements
FGFR2	8	2 (3.1%)	6 (1.2%)	0.518

CNV copy number variations, INDEL short and long insertion/deletion, MSI microsatellite instability, MSI-H microsatellite instability-high, MSS microsatellite stable, PC poorly cohesive, SNV single nucleotide variant, TMB tumor mutation burden, TMB-H tumor mutational burden-high, TMB-L tumor mutational burden-low
^aTumors with TMB < 10 Muts/Mb are defined as TMB-L, while ≥ 10 Muts/Mb defined as TMB-H
^bPearson’s Chi-square test (or Fisher’s exact test) was used in statistical analyses. Values in italic are statistically significant

ISSN: 1479-5876